Manish A Shah
Cornell University
H-index: 75
North America-United States
Top articles of Manish A Shah
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients | European Journal of Cancer | Julie R Brahmer Georgina V Long Omid Hamid Edward B Garon Roy S Herbst | 2024/3/1 |
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. | Manish A Shah Kohei Shitara Sara Lonardi Yee Chao Kensei Yamaguchi | 2024/1/20 | |
Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial). | Leon Pappas Rona Yaeger Pashtoon Murtaza Kasi Manish A Shah Nilofer Saba Azad | 2024/1/20 | |
Catheter tip for a catheter assembly | 2024/4/2 | ||
Gastric Cancer Tumor Immune Microenvironment Landscape: Clinical Implications for Patient Outcome and Response to PD-1 Immune Checkpoint Blockade | Manish Shah Sandipto Sarkar Daria Melikhova Prashant Thakkar Olga Kudryashova | 2024/3/26 | |
LEAP-014: first-line lenvatinib+ pembrolizumab+ chemotherapy in advanced/metastatic esophageal squamous cell carcinoma | Jong-Mu Sun Antoine Adenis Peter C Enzinger Manish A Shah Ken Kato | 2024/3 | |
135MO Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+ mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2 … | Annals of Oncology | JA Ajani F Lordick YJ Bang PC Enzinger DH Ilson | 2023/11/1 |
Histopathologic “Evolution” in Pediatric Primary Intracranial High-Grade Sarcoma-a Key that Unlocked the Correct Diagnosis | Annals of Clinical & Laboratory Science | Udit Naik Manish Shah David I Sandberg Rohan Samant Angshumoy Roy | 2023/7/1 |
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer | Journal for immunotherapy of cancer | Leisha A Emens Sylvia Adams Ashley Cimino-Mathews Mary L Disis Margaret E Gatti-Mays | 2021 |
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Q and A | JCO Oncology Practice | Lakshmi Rajdev Erin B Kennedy Manish A Shah | 2023/4 |
586 Phase II study of Telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma | Sandipto Sarkar Sahrish Khan Jennifer Rachel Eads Reem Sharaiha David Carr-Locke | 2023/11/1 | |
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial | Gastric Cancer | Josep Tabernero Paulo M Hoff Lin Shen Atsushi Ohtsu Manish A Shah | 2023/1 |
Global prevalence of CLDN18. 2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker … | Kohei Shitara Rui-Hua Xu Diarmuid Martin Moran Abraham Guerrero Ran Li | 2023/6/1 | |
Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III canStem303C study | Clinical colorectal cancer | Manish A Shah Takayuki Yoshino Niall C Tebbutt Axel Grothey Josep Tabernero | 2023/3/1 |
LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+ mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2 … | Annals of Oncology | JA Ajani F Lordick YJ Bang PC Enzinger DH Ilson | 2023/10/1 |
High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic … | Uqba Khan Ilkay Us Jenna Moyer Pashtoon Murtaza Kasi Allyson J Ocean | 2023/6/1 | |
Genomic and immune landscape of ERBB2/ERBB3 alterations in gastroesophageal adenocarcinoma. | Sarbajit Mukherjee Elizabeth Mauer Karyn Ronski Manish A Shah | 2023/2/1 | |
Prediction of Venous Thromboembolism in Patients with Cancer Using Neural Network | Blood | Romy De Laat-Kremers Scott Tagawa Madeline Young Christine Garcia Manish Shah | 2023/11/28 |
LBA81 Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab+ CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive … | Annals of Oncology | F Lordick MA Shah K Shitara JA Ajani YJ Bang | 2023/10/1 |
Zolbetuximab+ mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18. 2+)/HER2− locally advanced (LA) unresectable or metastatic gastric or … | Kohei Shitara Florian Lordick Yung-Jue Bang Peter C Enzinger David H Ilson | 2023/2/1 |
Co-Authors
